FDA approves new dosage of Faslodex
WILMINGTON, Del. The Food and Drug Administration has approved a new dosage of an AstraZeneca drug for treating breast cancer, AstraZeneca said Friday.
The Anglo-Swedish drug maker announced the approval of the 500-mg dose of the injected drug Faslodex (fulvestrant) for treating breast cancer that has spread to other parts of the body –– also known as metastasis –– in postmenopausal women after they have received anti-estrogen therapy. The new dosage replaces the previous 250-mg dose of the drug.
“This approval is an important advancement for women with metastatic breast cancer, where the treatment approach is centered on delaying disease progression,” AstraZeneca medical director Gershon Locker said. “Faslodex at 250 mg has been an important treatment option for many women, and we now have data to show that the new 500-mg dosing regimen can improve progression-free survival compared with the 250-mg dose.”
Artificial Life launches GluCoMo app for diabetics
LOS ANGELES A leading provider of award-winning mobile 3G technology and applications recently launched a mobile app for diabetics.
Artificial Life said its app GluCoMo (short for glucose monitor) is an electronic diary and reminder system that keeps track of many diabetes-related activities in one centralized mobile hub. The comprehensive readings recorded within the app include: blood sugar level, insulin intake, weight, pulse, physical activity, dietary intake, blood pressure and medication intake. GluCoMo users also may adjust their activities by reviewing their entry history through easy-to-use informative graph visualizations, and set up automatic reminders to alert themselves of different health-related activities, Artificial Life said.
GluCoMo is available for download on Apple’s app store.
PhRMA: Drug, vaccine development for infectious diseases grows
BOSTON Close to 400 drugs and vaccines are in development for fighting infectious diseases, according to one of the pharmaceutical industry’s largest lobbying groups.
The Pharmaceutical Research and Manufacturers of America announced Friday that drug makers have 395 new medicines and vaccines in clinical development or under review by the Food and Drug Administration. These include five vaccines and six drugs for malaria, as well as agents for infections like cholera, methicillin-resistant Staphylococcus aureus and the Ebola virus.
“Infectious diseases continue to cause great human suffering, and the effort to conquer them is one of the greatest human endeavors,” PhRMA president and CEO John Castellani said. “Many once-deadly diseases have been nearly wiped out or are effectively controlled thanks to medical progress, but much more needs to be done.”